FAPI pet scan for brain metastases from her2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is testing a new type of PET scan (called FAPI) to see if it can help predict how well T-DXd (Enhertu) works on breast cancer that has spread to the brain. Participants will get T-DXd as planned and have the scan before starting treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are generally able to care for yourself (Easter Cooperative Oncology Group score 0-2).
- Your breast cancer is HER2-positive (confirmed by a biopsy).
- You have at least one brain metastasis that was not treated with radiation and is at least 1 cm in size (seen on MRI).
- You have not had T-DXd (Enhertu) before.
- Your organs (bone marrow, liver, kidneys, heart) are working well enough for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a drug called trastuzumab deruxtecan works in people with HER2-low breast cancer that has spread to other parts of the body. It uses PET-CT scans to check the tumor's response to treatment.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
This trial tests whether a special PET/CT scan using a tracer called FAPI can better detect if breast cancer has spread to lymph nodes under the arm after neoadjuvant treatment. If successful, it could guide more precise surgery and avoid unnecessary lymph node removal.
This study tests a new imaging agent (18F-FAPI-04) for PET scans to see if it can better detect breast cancer or its spread. It may help doctors find tumors more clearly.
This trial tests a new imaging test (a special PET scan) that can see HER2 proteins in breast cancer tumors. It is for people who are already getting treatment before surgery to see if the scan helps doctors understand how well the therapy is working.
This trial tests a combination of a targeted cancer drug (T-DXd) with precise radiation to the brain for people with HER2-positive breast cancer that has spread to the brain. It aims to see if this combination can better control the brain tumors while being safe.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.